X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (553) 553
Book Review (169) 169
Newsletter (78) 78
Newspaper Article (49) 49
Publication (44) 44
Transcript (15) 15
Conference Proceeding (7) 7
Book Chapter (4) 4
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
treprostinil (543) 543
index medicus (364) 364
pulmonary hypertension (341) 341
humans (339) 339
hypertension, pulmonary - drug therapy (257) 257
pulmonary arterial hypertension (224) 224
prostacyclin (177) 177
epoprostenol (173) 173
epoprostenol - analogs & derivatives (169) 169
female (166) 166
respiratory system (164) 164
male (163) 163
cardiac & cardiovascular systems (139) 139
therapy (132) 132
hypertension, pulmonary - physiopathology (123) 123
pharmacology & pharmacy (123) 123
antihypertensive agents - therapeutic use (121) 121
bosentan (121) 121
survival (120) 120
adult (118) 118
middle aged (118) 118
antihypertensive agents - administration & dosage (117) 117
double-blind (115) 115
treatment outcome (115) 115
epoprostenol - administration & dosage (114) 114
care and treatment (100) 100
epoprostenol - therapeutic use (99) 99
iloprost (98) 98
drug therapy (97) 97
inhaled iloprost (96) 96
sildenafil (94) 94
oral treprostinil (92) 92
5 inhibitor therapy (81) 81
hypertension (80) 80
arterial-hypertension (79) 79
continuous intravenous epoprostenol (74) 74
endothelin receptor antagonist (74) 74
research (72) 72
abridged index medicus (71) 71
aged (68) 68
efficacy (68) 68
prostacyclin analog (68) 68
antihypertensive agents - adverse effects (67) 67
epoprostenol - adverse effects (66) 66
familial primary pulmonary hypertension (60) 60
randomized controlled-trial (59) 59
drug therapy, combination (58) 58
infusion (58) 58
controlled-trial (55) 55
dosage and administration (54) 54
subcutaneous treprostinil (54) 54
diagnosis (51) 51
intellectual property (51) 51
adolescent (49) 49
pharmacokinetics (46) 46
medicine, general & internal (45) 45
combination therapy (44) 44
hypertension, pulmonary - diagnosis (44) 44
placebo-controlled trial (43) 43
safety (42) 42
dose-response relationship, drug (41) 41
health aspects (41) 41
critical care medicine (39) 39
hypertension, pulmonary - mortality (39) 39
analysis (38) 38
pharmaceutical industry (38) 38
pulmonary arteries (38) 38
administration, oral (37) 37
endothelin receptor antagonists (37) 37
mortality (36) 36
retrospective studies (36) 36
young adult (36) 36
prostanoids (35) 35
sildenafil citrate (35) 35
child (34) 34
clinical trials (34) 34
pulmonary/respiratory (34) 34
animals (33) 33
infusions, intravenous (33) 33
inhaled treprostinil (33) 33
medicine & public health (33) 33
patients (33) 33
reports (33) 33
tadalafil (33) 33
complications and side effects (32) 32
follow-up studies (32) 32
hypertension, pulmonary - etiology (32) 32
management (32) 32
prostaglandins (32) 32
surgery (32) 32
administration, inhalation (31) 31
disease (31) 31
intravenous epoprostenol (31) 31
prostaglandins - therapeutic use (31) 31
registry (31) 31
sulfonamides - therapeutic use (31) 31
time factors (31) 31
vasodilator agents - therapeutic use (31) 31
bosentan therapy (30) 30
drugs (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (656) 656
Spanish (23) 23
German (5) 5
French (4) 4
Russian (4) 4
Polish (3) 3
Portuguese (3) 3
Japanese (2) 2
Czech (1) 1
Italian (1) 1
Slovak (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


La Revue de medecine interne, ISSN 0248-8663, 06/2019, Volume 40, p. A113
La maladie de Degos ou papuloseatrophiante maligne est une pathologie multi systemiquevaso-occlusive rare des petits vaisseaux, d'etiologie inconnue, decrite... 
Treprostinil
Journal Article
Chest, ISSN 0012-3692, 2016, Volume 149, Issue 5, pp. 1234 - 1244
Background In recent years, the population of patients with pulmonary arterial hypertension (PAH) has changed dramatically, including more advanced age at... 
Pulmonary/Respiratory | outcomes | pulmonary arterial hypertension | pulmonary hypertension | age | Pulmonary arterial hypertension | Age | Outcomes | Pulmonary hypertension | 5 INHIBITOR THERAPY | REGISTRIES | HEART-FAILURE | PRESERVED EJECTION FRACTION | RANDOMIZED CONTROLLED-TRIAL | TADALAFIL | ENDOTHELIN RECEPTOR ANTAGONIST | 6-MINUTE WALK | RESPIRATORY SYSTEM | ORAL TREPROSTINIL | EPIDEMIOLOGY | CRITICAL CARE MEDICINE | Multivariate Analysis | Age Factors | Vasodilator Agents - therapeutic use | Humans | Middle Aged | Pulmonary Wedge Pressure | Male | Treatment Outcome | Antihypertensive Agents - therapeutic use | Randomized Controlled Trials as Topic | Epoprostenol - therapeutic use | Epoprostenol - analogs & derivatives | Phenotype | Female | Aged | Hypertension, Pulmonary - drug therapy | Tadalafil - therapeutic use | Walk Test | Hypertension, Pulmonary - etiology | Connective Tissue Diseases - complications | Care and treatment | Prognosis | Aged patients | Research | Health aspects | Causes and theories of causation | Diseases | Index Medicus | Abridged Index Medicus | PAWP, pulmonary artery wedge pressure | FREEDOM-C2 (F-C2), Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension | S+T, SC-TRE and TRUST | TRIUMPH, Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension | ERA, endothelin receptor antagonists | Original Research | PHIRST, Pulmonary Arterial Hypertension and Response to Tadalafil | SC-TRE, Subcutaneous Infusion of Treprostinil in Patients with PAH | PVR, pulmonary vascular resistance | REVEAL, Registry to Evaluate Early and Long-term PAH Disease Management | PH, pulmonary hypertension | PAH, pulmonary arterial hypertension | WHO, World Health Organization | Pulmonary Vascular Disease | 6MWD, 6-min walk distance | or PDE-5I for the Treatment of PAH | COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension | PDE-5I, phosphodiesterase type 5 inhibitors | TRUST, Study of Intravenous Remodulin in Patients in India with PAH | FREEDOM-M (F-M), Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension | mPAP, mean pulmonary artery pressure | CTD, connective tissue disease | FREEDOM-C (F-C), Oral Treprostinil in Combination With an ERA and
Journal Article
Journal Article
Journal of Pediatrics, ISSN 0022-3476, 03/2019, Volume 206, pp. 305 - 306
Journal Article
The Journal of Pediatrics, ISSN 0022-3476, 03/2019, Volume 206, pp. 305 - 306
Journal Article
Circulation, ISSN 0009-7322, 02/2013, Volume 127, Issue 5, pp. 624 - 633
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 04/2018, Volume 49, pp. 104 - 111
INS1009 is a long acting pulmonary vasodilator prodrug of treprostinil (TRE) that is formulated in a lipid nanoparticle for inhaled delivery by nebulization.... 
Pulmonary vasodilation | Treprostinil | Rats | Local lung effect | Hexadecyl-treprostinil prodrug | Dogs | VASORELAXATION | AEROSOL | INHIBITION | RESPIRATORY SYSTEM | PROSTACYCLIN ANALOG | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | ORAL TREPROSTINIL | RECEPTORS | HYPERTENSION | PROSTAGLANDIN E-2 | VASOCONSTRICTION | Index Medicus
Journal Article
Journal Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 2013, Volume 32, Issue 9, pp. 889 - 896
Journal Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 07/2019, Volume 38, Issue 7, pp. 748 - 756
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 809 - 818
Journal Article
Journal of Pharmacy Practice, ISSN 0897-1900, 2018, pp. 897190018764585 - 897190018764585
Treprostinil diolamine is the first oral dosage preparation of a prostacyclin analogue for use in treatment naive pulmonary arterial hypertension (PAH). This... 
prostacyclin | oral treprostinil | pulmonary hypertension | transition | switch
Journal Article
Lung, ISSN 0341-2040, 6/2018, Volume 196, Issue 3, pp. 305 - 312
Journal Article
Chest, ISSN 0012-3692, 07/2008, Volume 134, Issue 1, pp. 139 - 145
Background: Treprostinil, a long-acting prostacyclin analog, diminished the symptoms of pulmonary arterial hypertension (PAH) in controlled 12-week clinical... 
Treprostinil sodium | Prostacyclin | Bosentan | Pulmonary hypertension | Combination drug therapy
Journal Article
CLINICAL TOXICOLOGY, ISSN 1556-3650, 2017, Volume 55, Issue 7, pp. 712 - 713
Conference Proceeding
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Journal Article